Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06412666 is registered in ClinicalTrials.gov with Cytokinetics as lead sponsor.

NCT NCT06412666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06412666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Lead sponsor
Cytokinetics
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
May 29, 2024
Completion date
January 31, 2030
Enrollment
65 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric, symptomatic obstructive hypertrophic cardiomyopathy